CD8A and neoplasm: Besides, BTH-1677 can inhibit the suppressive activity of Tregs on CD4+ T cells and is able, when treated with whole blood, to enhance CD4+ and CD8+ T cell proliferation, also by driving T cell polarization towards anti-tumor Th1 phenotype [90, 91].